PW Medtech's Sichuan Ruijian Medical sees strong Q1 growth

PW Medtech Group (HKEX:1358) announced that its subsidiary, Sichuan Ruijian Medical, experienced significant growth in the first quarter of 2025. Revenue for the period ended March 31, 2025, reached CNY145,036,095.85, a 43.89% increase compared to the same period in the previous year. Profit before tax increased by 16.96% to CNY42,782,684.84, while profit for the year rose by 11.66% to CNY34,875,475.45. Profit attributable to the shareholders of Sichuan Ruijian Medical was CNY36,171,069.91, an increase of 15.68%. The company attributed this growth to its expansion in domestic and overseas markets and increased brand awareness. Sichuan Ruijian Medical is a medical device company focused on research, development, manufacturing, and sales of blood purification devices.